Event: Detect, Protect, Prevent: Improving uACR Testing and ACE/ARB Deployment to Reduce Kidney and Cardiovascular Risk - A Masterclass for Primary Care

Join us on the 9^th June from 12:30pm to 13:30pm

The Medicine Optimisation Scheme aims to improve early identification and management of chronic kidney disease (CKD) and reduce cardio-renal risk by increasing uACR testing and optimising ACEI/ARB prescribing. Open to primary care clinical staff – including nurses, practice pharmacists, and GPs

The session will be led by local nephrologists and include case studies and a panel discussion.

The session will cover the following areas:

1. Urine ACR Testing

• Importance of early CKD detection - the prognostic value of albuminuria as an early marker of kidney and cardiovascular disease – advantages over eGFR.
• At risk populations and recommendations for monitoring intervals.
• Interpreting uACR results - classification of albuminuria and using uACR results to stratify CKD risk.
• How albuminuria informs therapeutic decisions and referral.

1. ACE/ARB

• Pharmacology and mode of action
• Renal and cardiovascular benefits of RAAS inhibition.
• Benefits beyond blood pressure control and when to initiate in normotensive patients.
• Clinical Indications for starting ACE/ARB.
• Baseline checks and follow‑up monitoring
• What constitutes an acceptable creatinine rise or eGFR decline
• How to titrate to the highest tolerated dose.
• Understanding hyperkalaemia thresholds and management strategies
• When to continue vs pause vs stop ACE/ARB
• Managing symptomatic hypotension
• Handling patients with prior ACE/ARB ‘intolerance’
• Using uACR to monitor CKD progression and as a trigger for ACE/ARB intensification
• When to refer

Clinicians will leave the session with:

• Practical skills to support the medicines optimisation scheme and improve patient outcomes
• A more proactive approach to identifying cardio‑renal risk earlier in primary care.
• Greater diagnostic confidence in CKD detection.
• Better understanding of how to use uACR to guide management.
• Clearer clinical decision‑making pathways for CKD risk stratification and treatment escalation.
• Improved prescribing competence around ACEI/ARBs - initiation, titration, monitoring, and safety.

To register please click on the link: https://events.teams.microsoft.com/event/d27c9994-f723-4dc6-9ab2-b33031cd7c14@37c354b2-85b0-47f5-b222-07b48d774ee3